Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teriflunomide Phase 2 Extension in MS
NCT00228163Phase 2Completed
- Sponsor
- Sanofi
- Start
- Jan 2002
- Primary completion
- Jan 2015
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of teriflunomide in multiple sclerosis (MS) (2 arms), sponsored by Sanofi. Primary endpoint: Number of patients with adverse events at 532 weeks. Started Jan 2002; status: completed.
02
Drugs
teriflunomide
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT00228163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00228163.